Can H Pylori Cause Gastritis? | The Bacterial Link

Understanding the connection between H. pylori and gastritis is fundamental to digestive health. This common bacterium can quietly reside in the stomach, often for years, before its presence manifests as noticeable symptoms or complications. Unraveling how this microorganism interacts with our stomach lining offers clarity on a widespread health concern.

Understanding Gastritis

Gastritis refers to inflammation of the stomach lining, a condition that can range from a mild irritation to a severe, debilitating issue. This inflammation occurs when the protective mucosal barrier within the stomach is compromised, allowing digestive acids and enzymes to irritate the underlying tissue.

Symptoms of Gastritis

The manifestations of gastritis vary significantly among individuals, with some experiencing no symptoms at all, particularly in chronic cases. When symptoms do occur, they often include:

• Abdominal pain or discomfort, typically in the upper abdomen.
• Burning sensation in the stomach, often relieved by eating.
• Nausea and occasional vomiting.
• Feeling of fullness or bloating after eating.
• Loss of appetite.

In severe cases, gastritis can lead to stomach bleeding, which might present as black, tarry stools or vomiting blood, requiring immediate medical attention.

Types of Gastritis

Gastritis is broadly categorized into acute and chronic forms, based on the duration and nature of the inflammation.

1. Acute Gastritis: This type develops suddenly and involves a rapid onset of symptoms. It is often caused by factors such as excessive alcohol consumption, certain medications like NSAIDs, or severe stress. The inflammation is typically short-lived and resolves once the causative agent is removed or treated.
2. Chronic Gastritis: This form develops gradually over time and can persist for months or even years. It often results from persistent irritation or infection, with H. pylori being the most common cause globally. Chronic gastritis can lead to more significant changes in the stomach lining, including atrophy and metaplasia, if left untreated.

The H. pylori Bacterium

Helicobacter pylori is a spiral-shaped bacterium uniquely adapted to survive in the highly acidic environment of the human stomach. It is one of the most common chronic bacterial infections worldwide, affecting roughly half of the global population.

Survival in the Stomach

The stomach’s acidity is a formidable defense against most microorganisms, but H. pylori possesses a key enzyme called urease. Urease converts urea, a common compound in the stomach, into ammonia and carbon dioxide. The ammonia neutralizes the surrounding stomach acid, creating a protective cloud around the bacterium, allowing it to colonize the stomach lining effectively. This mechanism enables H. pylori to burrow into the mucus layer, attaching to epithelial cells beneath.

Prevalence and Transmission

H. pylori infection is more prevalent in developing countries, often linked to poor sanitation and hygiene. Transmission routes are primarily thought to be oral-oral or fecal-oral, meaning it can spread through contaminated food or water, or direct contact with an infected person’s saliva. Many individuals acquire the infection during childhood, and it can persist asymptomatically for decades.

The Direct Link: H. pylori and Gastritis

The presence of H. pylori in the stomach lining is a direct trigger for inflammation, leading to gastritis. The bacterium’s survival strategies and its interaction with host cells are central to this process.

Mechanism of Action

Once H. pylori colonizes the stomach, it initiates a cascade of events that damage the gastric mucosa. The urease activity, while protecting the bacterium, also produces ammonia, which is toxic to stomach cells. Additionally, H. pylori produces various virulence factors, including VacA (vacuolating cytotoxin A) and CagA (cytotoxin-associated gene A).

• VacA: This toxin can induce vacuole formation in gastric epithelial cells, disrupting their function and leading to cell death.
• CagA: Strains carrying the CagA gene are considered more virulent. CagA is injected directly into gastric epithelial cells, where it interferes with cellular signaling pathways, promotes inflammation, and can alter cell growth and differentiation.

These bacterial factors, combined with the host’s immune response, contribute to the ongoing inflammation characteristic of gastritis. For more detailed information on bacterial mechanisms, the CDC offers resources on infectious agents.

Inflammatory Response

The body’s immune system recognizes H. pylori as a foreign invader and mounts an inflammatory response. Immune cells, such as neutrophils, lymphocytes, and macrophages, infiltrate the gastric lining. While intended to clear the infection, this sustained immune activation releases pro-inflammatory cytokines and reactive oxygen species, which further damage the stomach cells and perpetuate the inflammatory cycle. This persistent inflammation is the definition of chronic gastritis.

Chronic Inflammation and Its Effects

Long-term inflammation caused by H. pylori can lead to significant changes in the stomach lining. This includes chronic active gastritis, where both acute and chronic inflammatory cells are present. Over time, the gastric glands can atrophy, meaning they shrink and lose their specialized cells, leading to a condition called atrophic gastritis. This can impair acid production and nutrient absorption.

Acute H. pylori Gastritis

Upon initial infection, some individuals may experience acute gastritis. This phase is characterized by a sudden onset of symptoms like nausea, vomiting, and upper abdominal pain. Histologically, acute H. pylori gastritis shows a prominent infiltration of neutrophils in the gastric mucosa. This acute phase often subsides, but the bacterium persists, leading to chronic infection.

Chronic H. pylori Gastritis

The more common and clinically significant form is chronic H. pylori gastritis. This involves a persistent inflammatory infiltrate dominated by lymphocytes and plasma cells, often accompanied by neutrophils. The inflammation is typically diffuse, affecting different parts of the stomach, but it can be more pronounced in the antrum (lower part of the stomach) or the corpus (main body of the stomach), depending on the specific strain and host factors. This long-standing inflammation is the precursor to many other gastric issues.

How H. pylori Causes Damage

The damage inflicted by H. pylori goes beyond simple inflammation. It involves a sophisticated interplay between bacterial factors and the host’s cellular responses, leading to a compromised stomach lining.

Mucosal Barrier Disruption

The stomach lining is protected by a thick layer of mucus and bicarbonate, which acts as a barrier against stomach acid. H. pylori weakens this barrier in several ways. The ammonia produced by urease can directly damage mucus-producing cells. Additionally, the bacteria can disrupt the tight junctions between epithelial cells, increasing the permeability of the stomach lining. This allows acid and pepsin to penetrate deeper into the tissue, exacerbating inflammation and causing cellular injury.

Immune System Activation

While the immune response aims to clear the infection, its prolonged activation can contribute to tissue damage. Chronic infiltration of inflammatory cells, such as neutrophils and lymphocytes, releases various mediators like cytokines (e.g., IL-8, TNF-α) and reactive oxygen species. These substances are toxic to host cells and can cause oxidative stress, DNA damage, and apoptosis (programmed cell death) in gastric epithelial cells, perpetuating the cycle of inflammation and damage.

Cellular Changes and Repair

The constant cycle of damage and repair in the stomach lining due to chronic H. pylori infection can lead to significant cellular changes. Over time, the normal gastric glands may be replaced by intestinal-type glands, a process known as intestinal metaplasia. This change is considered a precancerous lesion, as these altered cells are more susceptible to malignant transformation. The chronic irritation and inflammation also stimulate increased cell turnover, which can increase the risk of genetic mutations.

Diagnosing H. pylori Infection

Accurate diagnosis of H. pylori infection is crucial for effective treatment of gastritis and prevention of further complications. Several reliable methods are available.

Non-Invasive Tests

These tests are generally preferred as a first step due to their ease of use and patient comfort.

1. Urea Breath Test (UBT): This test detects the urease activity of H. pylori. The patient ingests a tablet or liquid containing urea labeled with a non-radioactive isotope. If H. pylori is present, its urease breaks down the urea into ammonia and labeled carbon dioxide, which is then exhaled and detected in a breath sample.
2. Stool Antigen Test (SAT): This test detects H. pylori antigens in a stool sample. It is highly accurate for both initial diagnosis and confirming eradication after treatment.
3. Serology (Blood Test): This test detects antibodies to H. pylori in the blood. While useful for initial diagnosis, it cannot distinguish between active and past infections, as antibodies can persist for a long time even after the bacteria have been cleared. Therefore, it is not suitable for confirming eradication.

Invasive Tests

These tests require an endoscopy, where a thin, flexible tube with a camera is inserted down the esophagus into the stomach.

1. Biopsy Urease Test (CLO test): During endoscopy, a small tissue sample (biopsy) is taken from the stomach lining and placed into a special medium containing urea and a pH indicator. If H. pylori is present, urease activity will produce ammonia, changing the pH and causing a color change in the medium. This test provides rapid results.
2. Histology: Biopsy samples can also be examined under a microscope by a pathologist. This method directly visualizes the bacteria and assesses the degree and type of inflammation, as well as any cellular changes like atrophy or metaplasia.
3. Culture: In some cases, especially when antibiotic resistance is suspected, biopsy samples can be cultured to grow the bacteria. This allows for antibiotic sensitivity testing to guide treatment.

Treating H. pylori Gastritis

The treatment for H. pylori infection, and consequently the gastritis it causes, centers on eradicating the bacterium from the stomach. This typically involves a combination of medications.

Eradication Therapy

Standard treatment regimens, often referred to as “triple therapy” or “quadruple therapy,” usually last for 10 to 14 days. These regimens combine:

• Antibiotics: Two or more antibiotics are used to target H. pylori, such as clarithromycin, amoxicillin, metronidazole, or tetracycline. Using multiple antibiotics helps to overcome potential resistance and increases the success rate of eradication.
• Proton Pump Inhibitor (PPI): A PPI (e.g., omeprazole, lansoprazole) reduces stomach acid production, which helps the antibiotics work more effectively and allows the inflamed stomach lining to heal.
• Bismuth Subsalicylate (in quadruple therapy): Bismuth compounds have direct antibacterial effects against H. pylori and can also protect the stomach lining.

Adherence to the full course of treatment is essential, even if symptoms improve, to ensure complete eradication and prevent recurrence. For general health information, the National Institute of Diabetes and Digestive and Kidney Diseases is a reliable source.

Post-Treatment Testing

After completing the eradication therapy, it is important to confirm that the H. pylori infection has been cleared. This is typically done using a urea breath test or a stool antigen test, performed at least four weeks after finishing antibiotics and two weeks after stopping PPIs. This waiting period ensures that the tests are not affected by residual medication, which could lead to false-negative results.

Beyond Gastritis: Other Complications

While gastritis is the direct and most common manifestation of H. pylori infection, the chronic inflammation can progress to more serious conditions if left untreated.

Peptic Ulcers

H. pylori is responsible for the vast majority of peptic ulcers, which are open sores that develop on the inside lining of the stomach (gastric ulcers) or the upper part of the small intestine (duodenal ulcers). The persistent inflammation and damage to the mucosal barrier allow stomach acid to erode the lining, leading to ulcer formation. Symptoms often include severe burning stomach pain, which may worsen on an empty stomach.

Gastric Cancer

Chronic H. pylori infection is a significant risk factor for certain types of gastric cancer. The World Health Organization has classified H. pylori as a Group 1 carcinogen. The long-term inflammation, leading to atrophic gastritis and intestinal metaplasia, creates an environment conducive to malignant transformation. Specifically, it is linked to:

• Gastric Adenocarcinoma: This is the most common type of stomach cancer. The progression from chronic gastritis to atrophy, metaplasia, dysplasia, and eventually adenocarcinoma is a well-recognized pathway.
• Gastric MALT Lymphoma: Mucosa-associated lymphoid tissue (MALT) lymphoma is a rare type of lymphoma that can develop in the stomach as a direct consequence of chronic immune stimulation by H. pylori. Eradication of the bacterium can often lead to regression of early-stage MALT lymphoma.

Preventing H. pylori Infection

While complete prevention can be challenging due to the bacterium’s widespread nature, certain practices can reduce the risk of acquiring H. pylori.

• Good Hygiene: Regular and thorough handwashing with soap and water, especially after using the restroom and before eating, is a simple yet effective measure.
• Safe Water Sources: Drinking water from safe, clean sources is important, particularly in areas where sanitation may be poor. Avoid consuming untreated water.
• Food Safety: Ensure food is prepared and cooked properly. Wash fruits and vegetables thoroughly before consumption.

These measures help minimize exposure to the bacteria and reduce the likelihood of infection, thereby lowering the risk of developing H. pylori-associated gastritis and its complications.